 Carcinoma, Transitional Cell
"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Descriptor ID |
D002295
|
| MeSH Number(s) |
C04.557.470.200.430
|
| Concept/Terms |
Carcinoma, Transitional Cell- Carcinoma, Transitional Cell
- Carcinomas, Transitional Cell
- Cell Carcinoma, Transitional
- Cell Carcinomas, Transitional
- Transitional Cell Carcinoma
- Transitional Cell Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".
This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 3 | 4 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2011 | 4 | 0 | 4 | | 2012 | 0 | 1 | 1 | | 2013 | 2 | 0 | 2 | | 2014 | 3 | 0 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 3 | 0 | 3 | | 2017 | 4 | 1 | 5 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 3 | 0 | 3 | | 2022 | 6 | 0 | 6 | | 2023 | 8 | 0 | 8 | | 2024 | 5 | 4 | 9 | | 2025 | 7 | 0 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.
-
Rizzo A, Zayed A, Vitale E, Buti S, Takeshita H, Crabb S, Roviello G, Seront E, Tapia JC, Scagliarini S, Popovic L, Kopp RM, Abahssain H, Rizzo M, Monteiro FSM, Massafra R, Brunetti O, Santini D, Ürün Y, Montironi R, Mollica V, Massari F, Soares A, Santoni M. Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset. Clin Exp Metastasis. 2025 Sep 06; 42(5):52.
-
Rizkalla CN, Tretiakova M, Suarez CJ, Williamson SR, Al-Obaidy KI, Acosta AM, Idrees MT, Chan E, Potterveld S, Sangoi AR. Urothelial carcinoma with osteoclast-like giant cells: An expanded immunohistochemical and molecular profile. Am J Clin Pathol. 2025 Aug 26; 164(2):257-264.
-
Rizzo M, Soares A, Gupta S, Calabrò F, Takeshita H, Bourlon MT, Park SH, Giannatempo P, Myint ZW, Büttner T, Grande E, Fiala O, Santini D, Bamias A, Zakopoulou R, Buti S, Kanesvaran R, Rescigno P, Molina-Cerrillo J, Epstein I, Marques Monteiro FS, Massari F, Porta C, Bellmunt J, Santoni M. Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study. JCO Glob Oncol. 2025 Jul; 11:e2400564.
-
Fahey CC, Clark-Garvey S, Porten S, Kamat AM, Flaig TW, Taylor JA, Kim WY, Milowsky MI. Mechanistic Insights and Future Directions for Enfortumab Vedotin in Urothelial Carcinoma: Highlights from the 10th Annual Leo & Anne Albert Institute for Bladder Cancer Care and Research Symposium. Curr Oncol. 2025 May 14; 32(5).
-
Sura S, Bupathi M, Morris V, Conkling P, Todoroff K, Bhanegaonkar A, Ike C. Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study. Curr Oncol. 2025 Mar 24; 32(4).
-
Incorvaia L, Scagliarini S, Marques Monteiro FS, Takeshita H, Tapia JC, Gandur Quiroga MN, Lam E, Tural D, Popovic L, Campos-Gomez S, Zucali PA, Mota A, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Abahssain H, Galosi AB, Badalamenti G, Kopecky J, Bamias A, Landmesser J, Ansari J, Calabrò F, Massari F, Buti S, Bellmunt J, Santoni M. Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab. Sci Rep. 2025 Mar 14; 15(1):8815.
-
Rizzo M, Morelli F, Ürün Y, Buti S, Park SH, Bourlon MT, Grande E, Massari F, Landmesser J, Poprach A, Takeshita H, Roviello G, Myint ZW, Popovic L, Soares A, Abahssain H, Giannatempo P, Molina-Cerrillo J, Incorvaia L, Salah S, Zeppellini A, Monteiro FSM, Porta C, Gupta S, Santoni M. Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience. Cancer Med. 2025 Feb; 14(4):e70479.
-
Fiala O, Massari F, Basso U, Giannatempo P, Grande E, Buti S, Myint ZW, De Giorgi U, Pichler R, Grillone F, Ürün Y, Calabrò F, Bourlon MT, Galli L, Kanesvaran R, Roviello G, Kucharz J, Rizzo M, Park SH, Cerbone L, Seront E, Messina C, Molina-Cerrillo J, Santini D, Yano A, Incorvaia L, Catalano M, Pinto A, Formisano L, Soares A, Facchini G, Fornarini G, Poprach A, Rebuzzi SE, Nasso C, Spinelli GP, Angel M, Stellato M, Tural D, Aurilio G, Epstein I, Carrozza F, Monteiro FSM, Benedetti G, Büchler T, Ortega C, Zakopoulou R, Battelli N, Porta C, Bellmunt J, Gupta S, Santoni M. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study. Target Oncol. 2024 Nov; 19(6):905-915.
-
Rizzo M, Soares A, Grande E, Bamias A, Kopp RM, Lenci E, Buttner T, Salah S, Grillone F, de Carvalho IT, Tapia JC, Gucciardino C, Pinto A, Mennitto A, Abahssain H, Rescigno P, Myint Z, Takeshita H, Spinelli GP, Popovic L, Vitale MG, Fiala O, Giannatempo P, Zakopoulou R, Carrozza F, Massari F, Monteiro FSM, Pace MP, Giannini M, Roviello G, Porta C, Battelli N, Kanesvaran R, Santoni M. Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study. Sci Rep. 2024 08 27; 14(1):19802.
-
Petrylak DP, Tagawa ST, Jain RK, Bupathi M, Balar A, Kalebasty AR, George S, Palmbos P, Nordquist L, Davis N, Ramamurthy C, Sternberg CN, Loriot Y, Agarwal N, Park C, Tonelli J, Vance M, Zhou H, Grivas P. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy. J Clin Oncol. 2024 Oct 10; 42(29):3410-3420.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|